Where the behavioral foundation was built.
Nine years in pharmaceutical marketing — from the field to brand management — shaped how I read people, markets and the decisions that move them.
EGPI — 9-year track record
Egyptian Group for Pharmaceutical Industries — among Egypt's top-30 by IMS. Progressed Medical Rep → Key Account Specialist → Associate Brand Manager → Brand Manager — across more than ten pharmaceutical brands, with a team of around fifty reps and six supervisors, covering all of Egypt.
Cardiovascular expertise
Specialized in cardiovascular and circulatory products — where every decision impacts lives. Scientific precision met market-driven storytelling.
Key Account Marketing
Acquisition and retention of key accounts, B2B relationship management, and strategic planning for high-value partnerships — aligning commercial goals with customer needs.
Awards & certification
"Best Achiever 2016" (nationwide, Egypt) and certified "Management Skills" by DSP Group — recognition built on consistent, measurable results.
Five rules I learned from a prescription pad.
Before I read a dashboard, I read why a doctor wouldn't prescribe a drug he knew worked. These five rules came out of real brands I launched or managed, and I still use every one of them with tech and e-commerce clients.
1. Authority travels down, never up
When I launched Vildabetes — a blood-glucose drug — from nothing, I didn't start with the broad base of physicians. I started with the professors at the old, established medical faculties, with conferences and scientific seminars, and positioned the brand as the first choice for one specific segment of diabetes patients.
The reason is behavioral, not commercial: prescribing behavior passes from teacher to student. Convince the professor and you don't need to convince the hundred doctors after him — you need to be there when they ask. The brand went on to sell strongly in the Egyptian market.
2. The barrier was social, not scientific
Vardenorect treats erectile dysfunction, and the obvious specialty to market it through is urology. But the category itself carries a social awkwardness that slows the conversation inside the clinic — friction that has nothing to do with the drug.
So I went to other specialties instead: obstetrics and gynaecology, and internal medicine. I built the message around low doses and their effect on the heart and circulation generally. The drug didn't change; the category it was read inside did, and the conversation moved out of an awkward place into an ordinary clinical one. That is exactly what I now call category framing.
3. The complaint was never about the drug
I positioned Egycusate as the first laxative in the Egyptian market to absorb both water and gas. The positioning was right, and the numbers still wouldn't move.
The reason wasn't efficacy and it wasn't price. It was the taste. We collected patient complaints, listened to them, and reformulated the taste to be palatable. The barrier stopping the decision was none of the arguments we were making — a lesson I return to every time a team sees a conversion problem and decides to cut the price.
4. The doctor protects himself before the patient
Noctiplon treats insomnia. Most drugs in that class are scheduled, meaning dispensing restrictions that put an administrative burden and an added liability on the prescriber.
So I built the positioning on precisely that point: this one sits outside that class. The barrier was never convincing the doctor of efficacy — it was the risk falling on him personally. It's the same thing I see in every buyer deciding under responsibility: a procurement manager, or a marketing director signing off a budget. Risk works on the decision before it works on the product.
5. Access isn't distribution — it's institutional trust
I was the point of contact between EGPI and Abbott: moving several products across to them, facilitating those sales on their behalf, and handling the Ministry of Health on marketing and publication approvals.
Doors like that don't open with a marketing message. They open by reading what the other side needs in order to say yes without taking on risk — the same skill that closes a technology partnership in the Gulf, in a different language.
Why a doctor makes a sharper marketer.
In pharma, you market to experts who challenge every claim, in a regulated space where trust is everything. It teaches you to lead with evidence, to segment with precision, and to understand the human behind the prescription. That discipline is exactly what relationship-driven GCC markets reward.
But the skill I value most from those years isn't a term from psychology. It's that a medical background lets me think like the doctor — to put myself in the customer's position and read the decision from where they sit, not from where I do.
Nine years in pharma taught me applied psychology, reading the other side, negotiation, personality types, and how to align my plan with a whole company's strategy. That is the layer I put over every campaign now, whether the buyer is a physician or a product manager at a tech company.